Bradykinin analysis revived – A validated method for determination of its stable metabolite in whole blood by LC–MS/MS

Seip, Knut Fredrik; Bjerknes, Kari C.; Johansen, Harald Thidemann; Landrø, Linn; Reubsaet, Léon

doi:10.1016/j.jchromb.2013.12.033

Cited by 16 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with results previously reported by many authors. [33,43,48,49] The deuterated BK added to plasma samples changed exactly in the same manner as its endogenous counterpart ( Fig. 7): determination of deuterated BK in plasma immediately after addition and after incubation for 24 h at 4°C revealed basically the same dramatic (several-fold) decrease in its concentration as in the case of native BK.…”

Section: Quantitation Of Endogenous Bk and Detection Of Deuterated Bkmentioning

confidence: 78%

“…Figure shows that initial plasma BK varied from 6.4 to 9.3 fmol/mL and such incubation resulted in a dramatic decrease in plasma BK concentrations (Table ). This is consistent with results previously reported by many authors …”

Section: Resultsmentioning

confidence: 99%

“…BK exhibits potent cardioprotective and hypotensive effects and with its metabolites is crucial for the treatment of type 2 diabetes mellitus and glioblastoma . The bradykinin receptors B1R and B2R are important targets for the development of alternative approaches to prostate cancer therapy . Thus, in this context, BK appears to be a good model molecule demonstrating applicability of uniformly deuterated peptides for quantitative liquid chromatography/mass spectrometry (LC/MS) analysis of peptides and their degradation metabolites.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Use of deuterium labeling by high‐temperature solid‐state hydrogen‐exchange reaction for mass spectrometric analysis of bradykinin biotransformation

Kopylov

Myasoedov

Dadayan

et al. 2016

Rapid Comm Mass Spectrometry

View full text Add to dashboard Cite

show abstract

Section: Quantitation Of Endogenous Bk and Detection Of Deuterated Bkmentioning

confidence: 78%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Use of deuterium labeling by high‐temperature solid‐state hydrogen‐exchange reaction for mass spectrometric analysis of bradykinin biotransformation

Kopylov

Myasoedov

Dadayan

et al. 2016

Rapid Comm Mass Spectrometry

View full text Add to dashboard Cite

show abstract

“…It is possible to determine (lys-)BK in plasma samples with a competition ELISA or via mass spectrometry. This latter technique also enables determination of BK breakdown products ( 9 ), which is associated with disease activity in HAE patients ( 10 ). While measuring BK directly might seem to be the most obvious (and direct) approach to discern plasma activation and the relationship to symptoms, available methods are particularly lengthy, technically challenging, and very dependent on care in sample collection.…”

Section: Bradykininmentioning

confidence: 99%

The Search for Biomarkers in Hereditary Angioedema

Kaplan

Maas

2017

Front. Med.

View full text Add to dashboard Cite

The unpredictable nature of attacks of tissue swelling in hereditary angioedema requires the identification of reliable biomarkers to monitor disease activity as well as response to therapy. At present, one can assess a C4 level (by ELISA) to assist in diagnosis but neither C4 nor C1 inhibitor levels reflect clinical course or prognosis. We will here review a collection of plasma proteins involved in blood coagulation, fibrinolysis, and innate immunity (Figure 1). A main focus is those proteins that are key to the formation of bradykinin (BK); namely, factor XII, plasma prekallikrein/kallikrein, high-molecular weight kininogen, and BK itself since overproduction of BK is key to the disease. Considerations include new approaches to measurement of active enzymes, ELISA methods that may supersede SDS gel analysis of bond cleavages, and examples of changes outside the BK cascade that may reflect when, where, and how an attack of swelling is initiated. We will discuss their usefulness as biomarker candidates, with pros and cons, and compare the analytical methods that are being developed to measure their levels or activity.

show abstract

“…Typically, only a few individuals presenting with nC1Inh‐HAE carry an F12 mutation . Vasoactive BK has been recognized as potentially the primary mediator responsible for increased vascular permeability in HAE pathophysiology . Once released, BK is rapidly metabolized, principally by angiotensin‐I‐converting enzyme (ACE) yet also by aminopeptidase P (APP), whereas carboxypeptidase N (CPN) transforms BK into its active metabolite: des Arg 9 ‐BK.…”

mentioning

confidence: 99%